IRIS UniCatt

Foa, Robin
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.335
EU - Europa 720
AS - Asia 477
SA - Sud America 102
AF - Africa 10
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 2.650
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.327
SE - Svezia 222
SG - Singapore 167
CN - Cina 159
IT - Italia 141
BR - Brasile 90
DE - Germania 85
IE - Irlanda 65
IN - India 61
PL - Polonia 58
FR - Francia 55
ID - Indonesia 37
GB - Regno Unito 23
RU - Federazione Russa 22
KR - Corea 13
FI - Finlandia 12
UA - Ucraina 11
TR - Turchia 10
AR - Argentina 9
AT - Austria 7
CA - Canada 6
AU - Australia 5
HK - Hong Kong 5
EG - Egitto 4
VN - Vietnam 4
CH - Svizzera 3
IQ - Iraq 3
MA - Marocco 3
BE - Belgio 2
CI - Costa d'Avorio 2
CZ - Repubblica Ceca 2
IR - Iran 2
JP - Giappone 2
KZ - Kazakistan 2
LT - Lituania 2
MX - Messico 2
NL - Olanda 2
PE - Perù 2
RO - Romania 2
UZ - Uzbekistan 2
AL - Albania 1
AZ - Azerbaigian 1
BD - Bangladesh 1
CY - Cipro 1
EU - Europa 1
GR - Grecia 1
IL - Israele 1
LI - Liechtenstein 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MN - Mongolia 1
PK - Pakistan 1
PT - Portogallo 1
PY - Paraguay 1
QA - Qatar 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TM - Turkmenistan 1
ZA - Sudafrica 1
Totale 2.650
Salva come PNG Salva come JPEG
Città #
Chandler 186
Singapore 105
Ashburn 61
Dublin 57
Warsaw 52
New York 48
Dearborn 44
Hyderabad 41
Florence 37
Jakarta 37
Princeton 27
Beijing 25
San Mateo 24
Wilmington 22
Frankfurt am Main 21
Milan 21
Redwood City 21
Hefei 19
Nanjing 18
Albany 16
Minneapolis 16
Los Angeles 15
Boston 13
Moscow 13
Nanchang 13
Pune 13
Seoul 13
Houston 12
Kunming 12
Düsseldorf 11
Lauterbourg 11
Norwalk 10
Chicago 9
Marseille 9
Izmir 8
Cattolica 7
Fairfield 7
Helsinki 7
Munich 7
São Paulo 7
Garden City 6
London 6
Rome 6
Seattle 6
Bologna 5
Changsha 5
Hong Kong 5
Jacksonville 5
Nuremberg 5
Wroclaw 5
Benalla 4
Buenos Aires 4
Engelhard 4
Genoa 4
Portsmouth 4
Shenyang 4
Vicopisano 4
Washington 4
Belo Horizonte 3
Columbus 3
Falls Church 3
Fremont 3
Mountain View 3
Padova 3
Sesto Fiorentino 3
Stockholm 3
Toronto 3
Turku 3
Abidjan 2
Andover 2
Arapiraca 2
Atlanta 2
Bari 2
Brasília 2
Brussels 2
Cairo 2
Catanduva 2
Chongqing 2
Colombo 2
Curitiba 2
Durham 2
Guarulhos 2
Gurgaon 2
Hanoi 2
Hebei 2
Jiaxing 2
Jinan 2
Lawrence 2
Lincoln 2
Manchester 2
Mirassol 2
Montes Claros 2
Ottawa 2
Redmond 2
Reggio Emilia 2
Rivalta Di Torino 2
San Jose 2
São José 2
São José do Rio Preto 2
Tashkent 2
Totale 1.275
Salva come PNG Salva come JPEG
Nome #
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation 609
Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia 136
Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: Correlation with biologically-based risk stratification 108
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors. A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (Gitmo) 103
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 76
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study 75
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments. 74
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 74
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 72
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study 71
Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma 70
Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia 68
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group 63
Anti-HLA donor-specific antibodies in allogeneic stem cell transplantation: management and desensitization protocol 60
Prognostic impact and risk factors of infections in patients with chronic lymphocytic leukemia treated with ibrutinib 60
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia 58
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 58
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study 57
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 56
Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. 55
A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia 54
Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases 50
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab 48
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter “Real-World” study 47
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report 47
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus 45
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study 44
Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: A Campus CLL report 43
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study 42
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia 42
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model 41
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL 39
Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab 37
Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment 35
BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study 34
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study 25
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study 18
Totale 2.694
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.971
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.971
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20209 0 0 0 0 0 0 0 0 0 0 0 9
2020/202170 2 8 3 7 11 9 8 1 5 5 7 4
2021/2022279 8 3 47 35 36 6 2 31 9 9 60 33
2022/2023489 64 73 32 58 37 67 14 31 65 7 31 10
2023/2024866 20 78 29 540 20 97 8 10 2 10 15 37
2024/2025645 24 16 47 23 49 35 22 32 93 134 157 13
Totale 2.694